Free · no account · quoted from the filing

What changed in ABT's 10-Q

Source: 10-Q filed 2026-04-29 · compared against 10-Q 2025-10-29. Every passage below is quoted verbatim from the filing itself.

Acquisition

This filing

On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation (Exact Sciences).

Segment Reporting

This filing

Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.

Revenue Growth

This filing

Total $ 11,164 $ 10,358

Segment Operating Earnings

This filing

Operating Earnings ... Total $ 2,904 $ 2,660

Liquidity and Debt

This filing

At March 31, 2026, Abbott’s long-term debt rating was A+ by S&P Global Ratings and Aa3 by Moody’s Investors Service.

Dividend

This filing

Abbott declared a quarterly dividend of $0.63 per share on its common shares, which represents an increase of 6.8 percent over the $0.59 per share dividend declared in the first quarter of 2025.

Remaining Performance Obligations

This filing

estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied ... was $ 6.2 billion in the Diagnostic Products segment, $ 429 million in the Medical Devices segment and $ 258 million in the Established Pharmaceuticals segment.

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.